Project description:We used the Human Transcriptome Array 2.0 expression data to examine quality control, reproducibility, and insights on differential gene expression inflammatory breast cancer biopsy specimens prior to systemic treatment.
Project description:In this study we generated gene expression profiles of 41 and 55 samples of patients with and without inflammatory breast cancer (IBC vs. non-IBC). The aim of the study was to delineate the specific transcriptional profile of the samples from patients with IBC in search for diagnostic, prognostic and predictive biomarkers.
Project description:Gene expression profiles were established for Inflammatory breast cancer samples from patients treated at the Institut Paoli-Calmettes.
Project description:The aim of this study was to compare the gene expression profile changes of DMBA-induced rat breast tumors from an initial stage to the moment of sacrifice. To this end, a cDNA microarray was performed (Affymetrix’s Rat Genome 230 2.0 array). This gene expression study was carried out on the umor biopsy samples and compared with matched tumor biopsy samples once the study ended (7 weeks after initial biopsy).
Project description:A gene expression profiling sub-study was conducted in which colonic biopsy samples were collected for RNA extraction and hybridization to microarrays from 48 patients with UC who were participating in ACT 1, a placebo-controlled study of infliximab. Gene expression profiles from infliximab responders were compared with those of baseline and infliximab non-responder samples. Infliximab had a significant effect on mRNA expression in treatment responders, with both infliximab dose and duration of treatment having an effect. Genes affected are primarily involved with inflammatory response, cell-mediated immune responses, and cell-to-cell signaling. Infliximab non-responders had a molecular phenotype that closely resembled that of untreated patients with UC. Unlike responders, non-responders do not effectively modulate TH1, TH2, and TH17 pathways. Gene expression can differentiate placebo and infliximab responders.